Patents by Inventor Matthias BIRTEL

Matthias BIRTEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11702631
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 18, 2023
    Inventors: Ralf Holger Voss, Ugur Sahin, Petra Oehm, Matthias Birtel, Janina Caspar
  • Publication number: 20230119334
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: August 21, 2022
    Publication date: April 20, 2023
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
  • Publication number: 20230000962
    Abstract: The present disclosure relates to methods for enhancing the efficiency of therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells, even when provided to a subject in sub-therapeutic amounts, are extremely effective in the treatment of cancer diseases, even those cancer diseases that are known to be difficult to treat with antigen receptor-engineered immune effector cells, such as solid tumors or cancers, if additionally target antigen for the antigen receptor is provided to the subject. Immune effector cells may be engineered ex vivo or in vitro and subsequently the immune effector cells may be administered to a subject in need of treatment, or immune effector cells may be engineered in vivo in a subject in need of treatment.
    Type: Application
    Filed: December 22, 2020
    Publication date: January 5, 2023
    Inventors: Arne BILLMEIER, Matthias BIRTEL, Nina HAYDUK, Veronika JAHNDEL, Oliver KLEIN, Kathrin KUNA, Kristina MICHEL, Petra OEHM, Yasmina OUCHAN, Katharina REINHARD, Benjamin RENGSTL, Ugur SAHIN
  • Publication number: 20220177544
    Abstract: The invention relates to variants of the alpha subunit of interleukin-2 receptor (IL2R) and interleukin-2 (IL2). In one embodiment, the IL2 variants described herein have amino acid substitutions at the region of IL2 that contacts the alpha (?) subunit of the heterotrimeric IL2 receptor complex, IL2R???, reducing its ability to bind and activate the heterotrimeric receptor complex. Conversely, the corresponding IL2R? variants described herein have amino acid substitutions compensating for such reduced ability of IL2 variants to bind to and activate IL2R???, preferably at amino acid residues contacted by IL2 amino acid residues that are substituted in the IL2 variants described herein.
    Type: Application
    Filed: March 16, 2020
    Publication date: June 9, 2022
    Inventors: Ugur Sahin, Sina Fellermeier-Kopf, Alexander Muik, Matthias Birtel
  • Publication number: 20220033461
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: September 18, 2021
    Publication date: February 3, 2022
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
  • Publication number: 20200063101
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: March 14, 2018
    Publication date: February 27, 2020
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Petra SIMON, Matthias BIRTEL, Janina CASPAR
  • Publication number: 20180282390
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 4, 2018
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL